Blueprint Medicines recently announced $50 million Series C round, meant to advance its two lead candidates through clinical trials in 2015 and fund the company's proprietary kinase discovery platform and pipeline.
Montréal et Lyon, le 20 novembre 2014 – NÉOMED et Biotech Finances conjuguent leurs expertises pour lancer BLOG.NEOMED.CA, un Ecosysblog® 100 % audio dont la vocation est de couvrir en français et en anglais l’actualité des acteurs de tous l
Pansements, compresses, orthèses ou stents, bandelettes de lecteurs de glycémie, les dispositifs médicaux sont souvent indispensables en complément d’un suivi ou d’un traitement pour de bons résultats de santé.
Researchers who have uncovered the 'monstrous' hidden nature of a molecule involved in prostate cancer say the findings could herald a new form of personalised medicine for patients, with doctors able to use the same molecular target for diagnosis...
Spending on medicines will rise 30% over the next five years, ballooning to $1.3 trillion in 2018, as about 200 new drugs come to market, patent-cliff expirations ebb, and demand grows worldwide—especially for newer specialty treatments in cancer and hepatitis C, a report by the IMS Institute for Healthcare Informatics has concluded.
A major challenge faced by the pharmaceutical industry has been how to rationally design and select protein molecules to create effective biologic drug therapies while reducing unintended side effects—a challenge that has largely been addressed...
Here’s another tech to file in the “boundless possibility of 3D printing” category: Two Swiss engineering professors are developing microscopic robots that will work inside the body to transport cargo – namely, drugs.
Following on from last month's initiatives from the US Treasury to modify the tax guidelines, there has been a distinct change in the deal flow. One of the big acquisition stories of 2014 has reached closure now that AbbVie is drawing a line under its planned acquisition of Shire and other companies are backing off or restructuring planned M&A.
The U.K. is striving to brand itself as a hotbed for biotech R&D, promising new funds for startups, pledging to speed up its approval process and courting some major players to deepen their roots in the country.
Le gouvernement a obtenu une baisse du prix de ce médicament, jugé initialement exorbitant. Une négociation loin d'être satisfaisante, selon Jean-François Corty, directeur Mission France de Médecins du monde.